Interim Results Announcement
Epistem Holdings Plc
28 February 2011
Epistem Plc (LSE: EHP), the rapidly growing UK Biotechnology and Personalised Medicine company will be announcing its interim results for the six months ended 31 December 2010 on Tuesday, 29 March 2011.
The analysts' meeting will be held at the offices of Peel Hunt LLP, 111 Old Broad Street, London EC2N 1PH at 10.00 am.
|
Epistem Plc |
|
|
|
Matthew Walls |
Chief Executive Officer |
+44 (0) 161 606 7258 |
|
John Rylands |
Finance Director |
+44 (0) 161 606 7244 |
|
|
|
|
|
Peel Hunt LLP |
|
|
|
James Steel |
|
+44 (0) 207 418 8900 |
|
Vijay Barathan |
|
+44 (0) 207 418 8900 |
|
|
|
|
|
De Facto Communications |
|
|
|
Mike Wort / Anna Dunphy |
|
+44 (0) 20 7861 3838 |
Notes to Editors:
About Epistem
Epistem is a biotechnology and Personalised Medicine company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics, biomarkers and diagnostics and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate.
Epistem operates three distinct business divisions, Contract Research Services, Novel Therapies and Personalised Medicine (biomarker and diagnostics).
This information is provided by RNS